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An improved understanding of human T cell-mediated immunity in
COVID-19 is important for optimizing therapeutic and vaccine strate-
gies. Experience with influenza shows that infection primes CD8+ T cell
memory to peptides presented by common HLA types like HLA-A2,
which enhances recovery and diminishes clinical severity upon rein-
fection. Stimulating peripheral blood mononuclear cells from
COVID-19 convalescent patients with overlapping peptides from se-
vere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) led to
the clonal expansion of SARS-CoV-2−specific CD8+ and CD4+ T cells
in vitro, with CD4+ T cells being robust. We identified two HLA-
A*02:01-restricted SARS-CoV-2-specfic CD8+ T cell epitopes, A2/
S269–277 and A2/Orf1ab3183–3191. Using peptide−HLA tetramer en-
richment, direct ex vivo assessment of A2/S269
+CD8+ and A2/
Orf1ab3183
+CD8+ populations indicated that A2/S269
+CD8+ T cells were
detected at comparable frequencies (∼1.3 × 10−5) in acute and conva-
lescent HLA-A*02:01+ patients. These frequencies were higher than
those found in uninfected HLA-A*02:01+ donors (∼2.5 × 10−6), but
low when compared to frequencies for influenza-specific (A2/M158)
and Epstein–Barr virus (EBV)-specific (A2/BMLF1280) (∼1.38 × 10−4) pop-
ulations. Phenotyping A2/S269
+CD8+ T cells from COVID-19 convalescents
ex vivo showed that A2/S269
+CD8+ T cells were predominantly negative
for CD38, HLA-DR, PD-1, and CD71 activation markers, although the
majority of total CD8+ T cells expressed granzymes and/or perforin. Fur-
thermore, the bias toward naïve, stem cell memory and central memory
A2/S269
+CD8+ T cells rather than effector memory populations suggests
that SARS-CoV-2 infection may be compromising CD8+ T cell activation.
Priming with appropriate vaccines may thus be beneficial for optimizing
CD8+ T cell immunity in COVID-19.
CD8+ T cells | COVID-19 | HLA-A*02:01 | SARS-CoV-2 epitopes
The current severe acute respiratory coronavirus 2 (SARS-CoV-2) pandemic has, as of September 2020, infected more than 25
million people, caused at least 850,000 deaths (1), and paralyzed
economies globally. Although the majority of infections are mild to
moderate and short in duration, ∼12 to 18% of COVID-19 pa-
tients develop severe disease requiring hospitalization, ∼5% are
critical (2–4), and others who are less severely affected, and even
asymptomatic, may still have some underlying pathology (5). These
are still early days, and there is much that remains unknown about
both the innate and adaptive immune responses in COVID-19. An
urgent need is to develop a better understanding so that any
immunopathology can be managed, and vaccine design and
immunotherapies optimized.
So far as adaptive immunity is concerned, we do know that
SARS-CoV-2−specific antibodies can be found in ∼95% of con-
valescent COVID-19 patients (6, 7) and that titers determined in
virus neutralization assays correlate well with spike protein-
binding immunoglobulin (Ig) levels measured by ELISA (8, 9).
High serum-neutralizing antibody titers tend to be more prominent
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in severe COVID-19, which could be characteristic of prolonged
antigen stimulation due to delayed virus clearance. Otherwise,
the duration of SARS-CoV-2−specific IgG persistence in serum
is far from clear, and we have much to learn about the CD4+ and
CD8+ T cell responses.
Virus-specific CD8+ T cells are generally thought to be in-
volved in the elimination of virus-infected cell “factories” in the
acute response to respiratory viruses with, where there is estab-
lished CD8+ T cell memory, that response being enhanced in
both rapidity and magnitude to provide a measure of protec-
tion against the development of severe disease following sec-
ondary virus challenge. Survivors of the 2002–2003 SARS
outbreak still maintain CD4+ and CD8+ T cell populations
reactive to the SARS-CoV-1 nucleocapsid protein (10), and evi-
dence of sustained T cell memory has also been found for Middle
East respiratory syndrome (MERS) (11). Furthermore, it is pos-
sible that there may be some cross-reactive T cell memory for
COVID-19 in people who have been infected with these viruses
and, perhaps, more broadly, with the previously circulating common
cold coronaviruses (12).
For SARS-CoV-2, there is growing evidence that virus-specific
T cells are indeed being generated. Our early COVID-19 case
study showed that both CD4+ T-follicular helper cells and acti-
vated CD38+HLA-DR+CD8+ T cells appeared in the patient’s
blood at 3 d prior to recovery, suggesting that they played a part
in the resolution of COVID-19 (13). Recent communications
from others also reported the presence SARS-CoV-2−reactive
CD4+ and CD8+ T cells in both acute and convalescent COVID-
19 patients (14, 15). More disturbing, however, is an analysis
suggesting that at least a proportion of the SARS-CoV-2−specific
CD8+ T cells recovered from peripheral blood may be showing as
an “exhausted” phenotype (16). Clearly, it is a matter of urgency
to develop a better understanding of the integrity of the acute
CD8+ T cell response in COVID-19 and how this impacts
disease outcome.
Here, we utilized a combination of peptide prediction and
in vitro peptide stimulation with overlapping peptides from the
spike (S), nucleocapsid (N), and membrane (M) proteins to
identify two SARS-CoV-2 epitopes restricted by HLA-A*02:01
(A2/S269 and A2/Orf1ab3183) in individuals with COVID-19. Using
peptide-HLA-I tetramers, we performed direct ex vivo tetramer
enrichment to define the frequency and activation profiles of the
responding SARS-CoV-2−specific CD8+ T cells in acute and
convalescent COVID-19 patients and in prepandemic peripheral
blood monocular cells (PBMCs), tonsil, and lung tissues from
uninfected donors.
Our data establish that HLA-A*02:01−restricted SARS-
CoV-2−reactive CD8+ T cells can be detected directly ex vivo
in both COVID-19 patients and in immunologically naïve indi-
viduals. However, while SARS-CoV-2−specific CD4+ T cell re-
sponses were broadly comparable to those found previously for
other viruses, virus-activated CD8+ T cells that recognize
SARS-CoV-2 peptides presented by the common (at least in
Caucasians) HLA-A*02:01 MHC-I glycoprotein both were at
low prevalence and express a less than optimal (for virus elimi-
nation) phenotype. These findings raise a number of questions.
Is this apparent CD8+ T cell response defect limited to these
particular epitopes? If so, are HLA-A*02:01 individuals at
higher relative risk? Alternatively, if this is a general effect, is the
SARS-CoV-2 virus in some way subverting CD8+ T cell re-
sponsiveness? Perhaps COVID-19 may be one disease where an
appropriately designed vaccine may do better than nature when
it comes to generating a protective CD8+ T cell recall response.
Results
COVID-19 Patient Cohort and Uninfected Controls. This study of
18 COVID-19 cases included one person who remained asymp-
tomatic, 10 who were symptomatic but were cared for at home,
and 7 who were admitted to hospital, including 2 requiring sup-
plemental oxygen (SI Appendix, Table S1). Control cells were
tested from another 17 uninfected individuals who formed a
control group (SI Appendix, Table S2). All COVID-19 patients
(median age 54 y, 55.6% females) seroconverted for SARS-CoV-2
antibodies by receptor-binding domain ELISA (17), and 12 were
HLA-A*02:01−expressing individuals. As controls, we analyzed
preexisting A2/CD8+ T cell responses in prepandemic PBMC and
tonsil samples from 12 HLA-A*02:01−expressing subjects across
three age groups: children (median age 9.5 y), adults (median age
51 y), and the elderly (median age 66.5 y), with 44% being female
(SI Appendix, Table S2). Additionally, we tested preexisting A2/
CD8+ T cell populations in lung tissues from five HLA-A2 indi-
viduals (median age 42 y).
CD4 + and CD8 + T Cell Responses to SARS-CoV-2 Overlapping Peptide
Pools. We first probed for SARS-CoV-2−specific CD4+ and
CD8+ T cells in convalescent COVID-19 donors using a stan-
dard 6-h intracellular cytokine staining (ICS) assay using peptide
pools containing 15mers, overlapping by 11 amino acids, which
spanned the entire N and M proteins and selected regions of
SARS-CoV-2 S protein. The PBMCs were stimulated with one
peptide pool and expanded for 10 d before the assessment of
SARS-CoV-2−reactive T cells by ICS for intracellular IFN-γ,
TNF, and MIP-1β, plus staining for CD107a and perforin (Fig. 1
and SI Appendix, Fig. S1A) using individual peptide pools. The
responding CD4+ T cells all stained for IFN-γ, TNF, MIP-1β,
CD107a, and perforin, while the CD8+ T cells were predomi-
nately positive for perforin (Fig. 1 A and B). The CD4+ T cells
showed significant staining for IFN-γ, with five out of six subjects
generating IFN-γ+CD4+ T cells responses to at least one of the
SARS-CoV-2 peptide N, M, or S pools, indicating that conva-
lescent COVID-19 patients have solid SARS-CoV-2−specific
CD4+ T cell immunity. However, while CD8+ T cells from 3/6
donors were perforin positive, evidence of modest IFN-γ+ acti-
vation for the CD8+ set was found in only one out of six donors.
It thus seems that IFN-γ−producing SARS-CoV-2−specific
CD4+ T cells expand to a much greater extent than the CD8+ set
following in vitro peptide stimulation (Fig. 1C).
Identification of SARS-CoV-2−Specific HLA-A*02:01−Restricted CD8 +
T Cell Epitopes. Switching the focus to HLA-specific SARS-CoV-2
CD8+ T cell responses, we next identified CD8+ T cell speci-
ficities for HLA-A*02:01−expressing individuals. Using pre-
dicted HLA-A*02:01−binding SARS-CoV-2−derived peptides
from the S, N, M, and Polyprotein1ab (Orf1ab) proteins (SI Ap-
pendix, Table S3; based on two prediction algorithms: NetCTLpan
and NetMHCpan; accessed 27 March 2020), PBMCs from five
HLA-A*02:01+ COVID-19 convalescent individuals were ex-
panded in vitro with a pool of 14 predicted A2/SARS-CoV-2
peptides for 10 d, then restimulated with individual peptides in an
ICS assay to determine peptide immunogenicity. Of the 14 pep-
tides screened, S269–277 (YLQPRTFLL) generated the strongest
CD8+IFN-γ+ response (mean 0.19%, n = 5), with lesser responses
being elicited for S976–984 (VLNDILSRL) and Orf1ab3183–3191
(FLLNKEMYL) (0.07% and 0.08%, respectively, mean, n = 5)
(Fig. 2 and SI Appendix, Fig. S1B). Collectively, we identified one
dominant and two subdominant A2/CD8+ T cell specificities for
SARS-CoV-2.
Peptide sequence conservation analysis for these SARS-
CoV-2 immunogenic peptides was extended to previously circu-
lating coronaviruses. Reference protein sequences for SARS-CoV-1
and MERS plus the “common cold” human CoV (hCoV) strains
229E, HKU1, NL63, and OC43 were obtained from National
Center for Biotechnology Information. Using the Virus Pathogen
Resource (https://www.viprbrc.org/brc/home.spg?decorator=vipr),
SARS-CoV2 S269, S976, and Orf1ab3183 peptide sequences were
compared to their respective protein sequences within each CoV
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strain (SI Appendix, Table S3). Our data showed that SARS-CoV-
2/Orf1ab3183 and S976 lacked any sequence similarity to hCoV
or MERS strains, but each shared 100% sequence identity
with SARS-CoV-1/Orf1ab3160–3168 (FLLNKEMYL) and S958–966
(VLNDILSRL), respectively. SARS-CoV-2/S269 shared 78% and
67% sequence identity with MERS/S317–325 (KLQPLTFLL) and
SARS-CoV-1/S256–264 (YLKPTTFML), respectively (positions
that differ are underlined). Evidently, the A2/SARS-CoV-2
CD8+ T cell epitopes identified may be cross-reactive for
SARS-CoV-1 and MERS, while they did not share homology
with the common cold hCoVs that circulate in Australia.
SARS-CoV-2−Specific A2/CD8 + T Cells Are at Low Frequency in COVID-
19 Patients. To further analyze the SARS-CoV-2−specific A2/CD8+
populations from COVID-19 patients, we generated tetramers
for the A2/S269 and A2/Orf1ab3183 epitopes. Tetramer-associated
Fig. 1. CD4+ and CD8+ T cell responses to SARS-CoV-2 overlapping peptide pools. (A) CD4+ and (B) CD8+ T cell responses to SARS-CoV2 S, M, and N peptide pools
in convalescent COVID-19 individuals. (i) Representative fluorescence-activated cell sorter (FACS) plots showing IFN-γ and TNF staining of (A) CD4+ or (B) CD8+ T cell
populations. (ii) Frequencies of IFN-γ+, TNF+, MIP-1β+, CD107a+ or perforin+ within the (A) CD4+ or (B) CD8+ T cells, with background staining subtracted (n = 6,
mean). Background staining values are shown in brackets. Data points show individual COVID-19 convalescent subjects. (C) Paired frequencies of IFN-γ+ CD4+ and
CD8+ T cells for S, N, and M peptide pools. Statistical significance was determined with Wilcoxon matched-pairs signed rank test, *P < 0.05.
Fig. 2. Identification of SARS-CoV-2−specific HLA-A*02:01−restricted CD8+ T cell epitopes. (A) Representative FACS plots of CD8+ IFN-γ/TNF staining after
stimulation with the SARS-CoV-2 predicted peptide pool and individual S269–277, S976–984, and Orf1ab3183–3191 peptides. (B) Frequency of IFN-γ+ of CD8+ T cells
for each SARS-CoV-2 peptide within the predicted peptide pool, with background staining subtracted (n = 5, mean). Peptide screen was performed in
convalescent COVID-19 PBMCs after 10-d expansion in vitro.
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magnetic enrichment (18, 19) was then used to determine the
ex vivo frequencies of A2/S269+CD8+ and A2/Orf1ab3183+CD8+
T cells in acute and convalescent HLA-A*02:01+ cases. During the
acute phase of COVID-19, A2/S269+CD8+ T cells were readily
detected after ex vivo tetramer enrichment at a mean frequency of
1.44 × 10−5 (n = 3) in the CD8+ set, while the values for the A2/
S269+CD8+ and A2/Orf1ab3183+CD8+ T cells from COVID-19
convalescents were 1.28 × 10−5 (n = 14) and 1.77 × 10−6 (n = 6),
respectively (Fig. 3 A and D). There was no significant difference in
the frequency of A2/S269+CD8+ T cells between acute and
Fig. 3. Low ex vivo frequency of SARS-CoV-2−specific A2/CD8+ T cell specificities in acute and convalescent COVID-19 patients. A2/S269+CD8+ and
A2/Orf1ab3183
+CD8+ T cells were identified directly ex vivo from healthy (pre−COVID-19) PBMCs, tonsils, and lungs, as well as acute and convalescent COVID-
19 PBMCs by tetramer magnetic enrichment. (A) Representative FACS plots of A2/S269
+CD8+ and A2/Orf1ab3183
+CD8+ T cells from enriched samples of (i) con-
valescent and (ii) acute COVID-19 PBMCs. (B) Representative FACS plots of A2/M158
+CD8+ and A2/BMLF1280
+CD8+ T cells from enriched healthy PBMCs. (C)
Representative FACS plots of A2/S269
+CD8+ and A2/Orf1ab3183
+CD8+ T cells from (i) enriched adult and elderly PBMCs, and child tonsils (T) and (ii) tetramer
staining of human lung tissue. (D) A2/CD8+ T cells precursor frequencies were calculated for A2/S269
+CD8+, A2/Orf1ab3183
+CD8+, A2/M158
+CD8+, and
A2/BMLF1280
+CD8+ T cells enriched from either PBMCs or tonsils, or stained in lungs. Dots represent individual donors. Means ± SEM are shown. Red dots are
COVID-19 acute (closed circle) and convalescent (open circle) donors. Black dots are healthy adult or elderly PBMCs (open circle), or MNCs from child tonsils
(closed circle). Donors with undetectable precursor frequencies of 0 are included on the graph to show the number of donors tested. These donors were not
included in statistical analyses. Statistical significance was determined with two-tailed Mann−Whitney U test, *P < 0.05, **P < 0.01, ***P < 0.001. (E) Rep-
resentative FACS plots and frequencies of A2/SARS-CoV-2+CD8+ T cells in the CD8+ population in healthy and convalescent donors on d0 and d10 of expansion.
Dots represent individual donors. Statistical significance was determined using a two-tailed Mann−Whitney U test, *P < 0.05.
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convalescent COVID-19 donors, while minimal A2/S269+CD8+ and
A2/Orf1ab3183+CD8+ T cells were detected in either unenriched or
flow-through samples (SI Appendix, Fig. S2). Indeed, while too few
T cells were available to test other specificities concurrently for the
COVID-19 patients, these frequencies of SARS-CoV-2−specific
CD8+ T cells were significantly lower than those found for influ-
enza A virus (IAV)-specific (1.39 × 10−4 for A2/M158; n = 6) and
Epstein–Barr virus (EBV)-specific (1.38 × 10−4 for A2/BMLF1280;
n = 6) memory T cell populations from uninfected controls (Fig. 3
B and D), and as per previous publications (19, 20).
Are SARS-CoV-2−specific CD8+ T cells present in uninfected
people? Using ex vivo tetramer enrichment with prepandemic
PBMC, tonsil, and lung samples taken from HLA-A*02:01−
expressing uninfected individuals (Fig. 3 C, i and D), naïve
SARS-CoV-2−specific CD8+ T cells directed at A2/S269 were
detected in all of the PBMC and tonsil samples (n = 12), while
CD8+ T cells directed at A2/Orf1ab3183 were found in only 33% of
individuals (n = 12), and the lung tissues were uniformly nega-
tive (Fig. 3 C, ii and D). Both the A2/S269+CD8+ and A2/
Orf1ab3183+CD8+ were found over a broad range of ages (A2/S269:
5 y to 68 y; A2/Orf1ab, 11 y to 65 y). Moreover, the A2/S269+CD8+
T cell frequency of 2.5 × 10−6 (mean, n = 12) in pre−COVID-19
healthy individuals was significantly lower than that found for
COVID-19−exposed individuals (P = 0.0064; Fig. 3D). It thus
seems that the A2/S269+CD8+ T cells are indeed being activated
and clonally expanded during SARS-CoV-2 infection. In contrast,
there was no significant difference in frequencies for the A2/
Orf1ab3183+CD8+ T cells from the prepandemic and COVID-19
groups (P = 0.4121) (Fig. 3D).
To further probe the responsiveness of A2/SARS-CoV-2
CD8+ T cells from uninfected versus convalescent COVID-19
donors, PBMCs or tonsil cells were stimulated with the S269 and
Orf1ab3183 peptides and cultured in vitro for 10 d. In prepan-
demic “naïve” subjects, no evidence of proliferation in culture
was found for the A2/S269+CD8+ or A2/Orf1ab3183+CD8+
sets (Fig. 3E). In contrast, both the A2/S269+CD8+ and A2/
Orf1ab3183+CD8+ T cells from the COVID-19 donors increased
significantly in numbers (P = 0.0357; Fig. 3E). Evidently, the
SARS-CoV-2/CD8+ T cells from COVID-19 individuals (but not
those from SARS-CoV-2 naïve subjects) were primed by
SARS-CoV-2 and are thus, at least under in vitro conditions,
capable of clonal expansion.
Activation Profiles of SARS-CoV-2−Specific A2/CD8 + T Cells Directly
Ex Vivo. The activation profiles of A2/S269+CD8+ T cells tested
directly ex vivo from acute and convalescent patients were
assessed by CD27, CD45RA, and CD95 staining to determine the
prevalence of the naïve (TNaïve) (CD27+CD45RA+CD95−), stem
cell memory (TSCM) (CD27+CD45RA+CD95+), central mem-
ory (TCM)-like (CD27+CD45RA−), effector memory (TEM)-like
(CD27−CD45RA−), and effector memory CD45RA (TEMRA)
(CD27−CD45RA+) subsets (Fig. 4A). Acute COVID-19 donors
displayed the highest proportion (mean of 92%) of TCM-like A2/
S269+CD8+ T cells and a low proportion of TEM-like CD8+
T cells. The A2/S269+ CD8+ T cells from the convalescent versus
acute subjects had a lower prevalence of TCM-like (mean of 50%)
cells, and larger proportions of the TNaïve (mean of 27%) and
TSCM (mean of 15%) sets, indicating that A2/S269+CD8+ T cells
expressing the optimally responsive TCM phenotype fall off rapidly
in blood sampled after the infection has resolved. Conversely, the
majority of A2/S269+CD8+ T cells within prepandemic children
and adults were naïve (TNaïve; mean of 68% and 77%, respec-
tively), while this subset was less prominent (mean of 46%) in the
elderly. Interestingly, older, uninfected people had a mean of 38%
TCM-like A2/S269+CD8+ T cells, similar to the frequency found
for COVID-19 convalescents (mean of 50%), but less than that for
IAV A2/M158 (mean of 66%).
The expression profiles for HLA-DR, CD38, PD-1, and CD71
were also determined for tetramer+ A2/S269+CD8+ T cells from
the COVID-19 patients (Fig. 4B). Only T cells from acutely in-
fected donors were positive for these activation markers, with the
majority coming from one individual (COVID-19 #2). In con-
trast, the A2/S269+CD8+ T cells from prepandemic and COVID-
19 convalescent subjects were characterized by minimal levels of
HLA-DR+CD38 and PD-1+CD71−, suggesting that, while the
A2/S269+CD8+ set can be activated during the acute phase of the
infection, it does not persist into short-term memory. Overall,
our data suggest that naïve A2/SARS-CoV-2−specific CD8+
T cells can indeed be expanded approximately fivefold and ac-
tivated during the acute phase of COVID-19 but that, atypically
for what we know for other readily resolved infections like in-
fluenza, both the extent of T cell proliferation and the persis-
tence of activated T cells in the blood is low for (days 37 to 101
post disease onset) convalescent individuals.
To further investigate the suboptimal activation of SARS-
CoV-2−specific CD8+ T cells in COVID-19, the killing capacity
of A2/S269+CD8+ T cells was assessed by staining for granzyme A,
B, and K, and perforin directly ex vivo. Surprisingly, the majority
of A2/S269+CD8+ T cells at both acute (mean of 77.2%) and
convalescent (mean of 72.4%) stages of COVID-19 expressed
three to four cytotoxic granzymes/perforin (Fig. 4C and SI Ap-
pendix, Fig. S3), indicating their activation status. However, a
similarly high expression level of granzymes/perforin was also found
on the majority of total CD8+ T cells (69 to 82.5%), as per our
previous case report (13), but not on non-CD8+ T cells (mean of 15
to 21%). As it is highly unlikely that ∼80% of all CD8+ T cells in
the peripheral blood during primary SARS-CoV-2 infection were
antigen specific (even if directed at several CD8+ T cell epitopes),
this suggests that a high proportion of CD8+ T cells are activated
via some “bystander”mechanism during acute/convalescent COVID-
19. The consequences, if any, of this effect for TCR-mediated acti-
vation merit further investigation.
Discussion
As the research community drives forward to design and evalu-
ate novel vaccines and immunotherapies for COVID-19, con-
current efforts directed at understanding how immunity works in
this disease process are largely focused on patient studies. Ap-
plying our established expertise in the analysis of T cell-mediated
immunity, we found here that the CD4+ “helper” T cell response
looks relatively normal when compared with what happens in, for
example, people who have been infected with an IAV. However,
when it comes to the virus-specific CD8+ T cells that play an
important role in ameliorating disease severity and driving re-
covery in other respiratory infections, our findings for COVID-
19 are less encouraging. Although we were able to identify two
SARS-CoV-2−specific CD8+ T cell epitopes associated with the
ubiquitous (in Caucasian) HLA-A*02:01 MHC-I glycoprotein
(A2/S269–277 and A2/Orf1ab3183–3191) and found evidence for
T cell responsiveness, the results were not what we expected.
Our findings show that, while “early memory” CD8+ T cells
can be detected in convalescent HLA-A*02:01 COVID-19 pa-
tients at frequencies approximately fivefold higher than those
from prepandemic samples, the SARS-CoV-2−specific response
was ∼10-fold lower than that found regularly for CD8+ T cells
directed at IAV or EBV epitopes. In general, there was an
overrepresentation of SARS-CoV-2−specific tetramer+CD8+
T cells expressing cell surface phenotypes that are considered to
be characteristic of “stem cell memory” and naïve precursor
status, suggesting that the infectious process is, in some way,
limiting both clonal expansion and differentiation of the “clas-
sical” effector and central memory sets. An alternative expla-
nation is, of course, that T cell effectors are being generated but
are localized to, and perhaps “consumed in” (driven to apoptosis?)
sites of virus-induced pathology.
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Fig. 4. Ex vivo activation profiles of SARS-CoV-2−specific A2/CD8+ T cells in COVID-19 subjects. (A) Overlaid FACS plots of A2/S269+CD8+ T cells from acute
COVID-19 (n = 3), convalescent COVID-19 (n = 11), healthy children (tonsils) (n = 4), healthy adults (n = 4), or healthy elderly donors (n = 4) show TNaïve
(CD27+CD45RA+CD95−), TSCM (CD27
+CD45RA+CD95+), TCM-like (CD27
+CD45RA−), TEM-like (CD27
−CD45RA−), and TEMRA (CD27
−CD45RA+) subsets. Pie charts
display the proportion of each phenotype subset based on the combined data per each COVID-19 or healthy donor group. Overlaid FACS plots of
A2/M158
+CD8+ and A2/BMLF1280
+CD8+ T cell memory phenotypes from healthy adults are also shown. (B) Overlaid FACS plots and combined frequencies of
A2/S269
+CD8+ T cells showing (i) HLA-DR and CD38 or (ii) PD-1 and CD71 activation markers for acute (n = 3), convalescent (n = 11) and healthy donors (n = 12).
(C) Overlaid FACS plots and combined frequencies of A2/S269
+CD8+ T cells showing granzyme A, B, and K, and perforin staining for acute (n = 2) and convalescent
(n = 3) donors. Representative FACS plots from one donor showing granzymes A, B, and K, and perforin of the total CD3+ T cell population. Combination
gating was used to determine the frequency of cells with one to four functions for A2/S269
+CD8+, total CD8+, or non-CD8+ T cells. Graphed data across multiple
COVID-19 acute, COVID-19 convalescent, or naïve subjects were combined for the activation and phenotypic analyses of A2/S269 CD8
+ T cells.
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Even so, it is the case that SARS-CoV-2−specific CD8+ T cells
were found in all COVID-19 acute and convalescent donors, and
in stored prepandemic PBMC and tonsil samples (but not lung
tissues) from HLA-A*02:01 children, mature adults, and the el-
derly. As the frequency of these naïve, prepandemic SARS-
CoV-2−specific CD8+ T cells (∼2.5 × 10−6) was numerically
comparable to that found for naïve HIV (Gag77–85, SLYNTVATL),
cancer (Survivin96–104), or Hepatitis C Virus (NS31073)-specific
CD8+ T cell populations in healthy HLA-A*02:01+ individuals
(19–21), both their presence and the fact that they were not readily
expanded following in vitro stimulation suggests that they were not
a product of prior exposure to some cross-reactive epitope. In fact,
these are likely the naïve precursors that would be stimulated by
appropriate prime-and-boost vaccine strategies.
Earlier experiments in a mouse model of SARS-CoV-1
showed that a conventional, CD8+ T cell-targeted prime-and-
boost approach indeed established substantial pools of memory
SARS-CoV-1−specific CD8+ T cells capable of driving protec-
tion against lethal SARS-CoV-1 infection (22). The fact that the
frequencies of A2/S269+CD8+ T cells in COVID-19 patients
increased approximately fivefold suggests that these SARS-
CoV-2−specific CD8+ T cells proliferated, to some extent,
during primary COVID-19, however not to the level of well-
established memory CD8+ T cell populations directed at other
viral epitopes like IAV-specific A2/M158 and EBV-specific A2/
BMLF1280. Further studies are obviously needed to understand
why this is so. In addition, as our acquaintance with this novel
CoV continues, we will be able to determine whether there is
long-term survival (at least at >1 y) of SARS-CoV-2−specific
CD8+ memory T cells following primary COVID-19 along with
whether, in now healthy survivors, they can be activated and clonally
expanded following challenge with an appropriate vaccine.
Surprisingly, the memory A2/S269+CD8+ T cell populations in
convalescent subjects were dominated by stem cell memory,
central memory, and naïve phenotypes, and lacked expression of
the CD38, HLA-DR, PD-1, and CD71 activation markers. This
is in stark contrast to the highly activated TEM and TEMRA
profiles found ex vivo in both short-term (day 25) and long-term
(7 mo) memory A2/M158+CD8+ T cells following avian A/H7N9
influenza infection (23, 24). These minimal activation profiles for
epitope-specific CD8+ T cells in early COVID-19 convalescence
could possibly reflect suboptimal priming of A2/S269+CD8+
T cells in primary COVID-19. Furthermore, a recent study by
Zhou et al. (25) demonstrated perturbed dendritic cell and T cell
function in SARS-CoV2 infection. Impaired dendritic cell
function might negatively impact antigen processing and pre-
sentation to CD8+ T cells, thus at least partially explaining the
limited differentiation of SARS-CoV-2−specific CD8+ T cells
observed here.
It remains unclear whether this is broadly representative of
primary CD8+ T cell responses in COVID-19 or specific to the
epitopes analyzed here. There is a possibility that there are other
HLA-A*02:01−restricted immunodominant epitopes, or even
immunodominant epitopes restricted by other HLAs in HLA-
A*02:01+ COVID-19 patients. The A2/S269 epitope identified in
our study was, however, also independently reported in a recent
preprint (26), suggesting it is a common HLA-A*02:01 epitope.
Moreover, it is also possible that CD8+ T cells directed toward
other HLA-A*02:01−restricted epitopes might have expressed
high levels of PD-1 and thus had an impaired capacity to expand
in vitro due to their exhausted phenotype. Further identification
of CD8+ T cell epitopes across a broad range of HLA class I
alleles and SARS-CoV-2 proteins is needed to provide a more
detailed landscape of CD8+ T cell responses in COVID-19, their
ex vivo frequencies, and activation profiles. In-depth analysis of
epitope-specific T cell responses in severe and critical cases is
also essential if we are to understand whether the activation
profiles of early CD8+ T cell memory reflect disease severity.
And, as the range of candidate vaccines that are tested through
phase 1 trials expands, it would also be of great benefit to de-
termine whether the characteristics of memory CD8+ T cells
generated in the absence of active infection look more optimal
than those described here.
Stimulation with overlapping peptides led to the expansion of
SARS-CoV-2−specific CD8+ and CD4+ T cells in vitro, although
CD4+ T cells dominated the response. This might support, at least
partially, the previous elegant study showing that CD4+ T cells but
not CD8+ T cells were of a greater importance in primary
SARS-CoV-1 infection, as depletion of CD4+ T cells (but not
CD8+ T cells) led to delayed viral clearance from the lungs, as-
sociated with reduced neutralizing antibody and cytokine pro-
duction (27). It is also important to note that the S peptide pool
from Miltenyi Biotec used here spans only selected regions (304 to
338, 421 to 475, 492 to 519, 683 to 707, 741 to 770, 785 to 802, and
885 to 1273) rather than the entire protein; thus some CD8+ and
CD4+ T cell responses could have been missed. Recent evidence
revealed that Th2 and Th17 cytokine profiles in COVID-19 pa-
tients can be associated with differential disease outcomes (28).
Our analyses focused on Th1 cytokine responses for CD4+ T cells,
leaving Th2 and Th17 cytokine responses unknown. Different
cytokine profiles of epitope-specific CD4+ T cells should be in-
vestigated in future studies, especially when SARS-CoV2−specific
CD4+ T cell epitopes are identified.
Our early report on immunity to COVID-19 in some of Aus-
tralia’s first patients suggested that broad and concomitant immune
responses were associated with recovery from mild-to-moderate
COVID-19 disease (13). The key immune populations detected
included antibody-secreting cells, helper follicular T cells, and ac-
tivated (CD38+HLA-DR+) CD8+ and CD4+ T cells, together
with progressive increases in SARS-CoV-2−specific IgM and IgG
antibodies. Subsequent studies confirmed the activation of both
CD4+ and CD8+ T cells as indicated by cell-surface marker ex-
pression (14, 15). The present much more extensive yet focused
analysis does, however, raise questions concerning the integrity of
the epitope-specific CD8+ T cell response in COVID-19. Given
the variation in disease outcome with this infection, that obviously
merits much more detailed analysis.
Methods
Study Participants and Ethics Statement. Thirty-five subjects were recruited
into this study. Acute and convalescent COVID-19 subjects were recruited via
the Alfred Hospital, University of Melbourne, or James Cook University.
Seven of the donors were admitted to hospital during their active infection
(SI Appendix, Table S1). Acute COVID-19 cases were admitted to the hospital
ward, with two patients requiring oxygen support (SI Appendix, Table S1).
Healthy donors were recruited via University of Melbourne or buffy packs
obtained from the Australian Red Cross LifeBlood (SI Appendix, Table S2).
Tonsils were obtained from healthy individuals undergoing tonsillectomy
(Tasmania, Australia). Lung samples were obtained prior to the COVID-19
pandemic via the Alfred Hospital’s Lung Tissue Biobank. All blood and tonsil
donors were HLA typed by Victorian Transplantation and Immunogenetics
Service. Peripheral blood was collected in heparinized tubes, and PBMCs
were isolated via Ficoll−Paque separation.
Experiments conformed to the Declaration of Helsinki Principles and the
Australian National Health and Medical Research Council Code of Practice.
Written informed consents were obtained from all blood donors prior to the
study. Lung tissues were obtained from deceased organ donors after written
informed consents from the next of kin. Written informed consents were
obtained from participants’ parents or guardians for underage tonsil tissue
donors. The study was approved by the Alfred Hospital (#280/14), The Uni-
versity of Melbourne (#2056689, #2056761, #1442952, #1955465, and
#1443389), the Australian Red Cross Lifeblood (ID 2015#8), the Tasmanian
Health and Medical (ID H0017479), and the James Cook University (H7886)
Human Research Ethics Committees.
Cell lines and reagents, ICS, ex vivo tetramer enrichment, and phenotypic
analysis are described in SI Appendix.
Data Availability. All study data are included in the article and SI Appendix.
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